---
document_datetime: 2025-11-23 08:05:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tolucombi.html
document_name: tolucombi.html
version: success
processing_time: 0.1430429
conversion_datetime: 2025-12-27 13:29:14.625473
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tolucombi

[RSS](/en/individual-human-medicine.xml/65696)

##### Authorised

This medicine is authorised for use in the European Union

telmisartan / hydrochlorothiazide

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Related information](#related-information-503)
- [More information on Tolucombi](#more-information-on-tolucombi-1058)
- [More information on Tolucombi](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Tolucombi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Tolucombi.

For practical information about using Tolucombi, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Tolucombi and what is it used for?

Tolucombi is a medicine that contains two active substances, telmisartan and hydrochlorothiazide. It is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by telmisartan alone. 'Essential' means that the hypertension has no obvious cause.

Tolucombi is a 'generic medicine'. This means that Tolucombi is similar to a 'reference medicine' already authorised in the European Union (EU) called MicardisPlus.

## How is Tolucombi used?

Tolucombi is available as tablets (40 mg or 80 mg telmisartan and 12.5 mg hydrochlorothiazide; 80 mg telmisartan and 25 mg hydrochlorothiazide) to be taken by mouth once a day with liquid. The dose of Tolucombi to be used depends on the dose of telmisartan that the patient was taking before: patients who were receiving 40 mg telmisartan should take the 40/12.5-mg tablets, and patients who were receiving 80 mg telmisartan should take the 80/12.5-mg tablets. The 80/25-mg tablets are used in patients whose blood pressure is not controlled using the 80/12.5-mg tablets or who have been stabilised using the two active substances taken separately before switching to Tolucombi.

The medicine can only be obtained with a prescription.

## How does Tolucombi work?

Tolucombi contains two active substances, telmisartan and hydrochlorothiazide.

Telmisartan is an 'angiotensin-II-receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen.

Hydrochlorothiazide is a diuretic, which is another type of treatment for hypertension. It works by increasing urine output, reducing the amount of fluid in the blood and reducing the blood pressure.

The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone. By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.

## How has Tolucombi been studied?

Because Tolucombi is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, MicardisPlus. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Tolucombi?

Because Tolucombi is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Tolucombi approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Tolucombi has been shown to have comparable quality and to be bioequivalent to MicardisPlus. Therefore, the CHMP's view was that, as for MicardisPlus, the benefit outweighs the identified risk. The Committee recommended that Tolucombi be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tolucombi?

A risk management plan has been developed to ensure that Tolucombi is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tolucombi, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Tolucombi

The European Commission granted a marketing authorisation valid throughout the European Union for Tolucombi on 13 March 2013.

For more information about treatment with Tolucombi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Tolucombi : EPAR - Summary for the public

Reference Number: EMA/40538/2013

English (EN) (75.2 KB - PDF)

**First published:** 08/04/2013

**Last updated:** 08/04/2013

[View](/en/documents/overview/tolucombi-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-965)

български (BG) (127.95 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/bg/documents/overview/tolucombi-epar-summary-public_bg.pdf)

español (ES) (97.32 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/es/documents/overview/tolucombi-epar-summary-public_es.pdf)

čeština (CS) (122.74 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/cs/documents/overview/tolucombi-epar-summary-public_cs.pdf)

dansk (DA) (96.23 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/da/documents/overview/tolucombi-epar-summary-public_da.pdf)

Deutsch (DE) (98.14 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/de/documents/overview/tolucombi-epar-summary-public_de.pdf)

eesti keel (ET) (73.52 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/et/documents/overview/tolucombi-epar-summary-public_et.pdf)

ελληνικά (EL) (127.42 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/el/documents/overview/tolucombi-epar-summary-public_el.pdf)

français (FR) (99.84 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/fr/documents/overview/tolucombi-epar-summary-public_fr.pdf)

italiano (IT) (76.13 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/it/documents/overview/tolucombi-epar-summary-public_it.pdf)

latviešu valoda (LV) (97.83 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/lv/documents/overview/tolucombi-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (98.09 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/lt/documents/overview/tolucombi-epar-summary-public_lt.pdf)

magyar (HU) (96.18 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/hu/documents/overview/tolucombi-epar-summary-public_hu.pdf)

Malti (MT) (102.31 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/mt/documents/overview/tolucombi-epar-summary-public_mt.pdf)

Nederlands (NL) (76.67 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/nl/documents/overview/tolucombi-epar-summary-public_nl.pdf)

polski (PL) (123.52 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/pl/documents/overview/tolucombi-epar-summary-public_pl.pdf)

português (PT) (99.13 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/pt/documents/overview/tolucombi-epar-summary-public_pt.pdf)

română (RO) (96.59 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/ro/documents/overview/tolucombi-epar-summary-public_ro.pdf)

slovenčina (SK) (122.79 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/sk/documents/overview/tolucombi-epar-summary-public_sk.pdf)

slovenščina (SL) (116.89 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/sl/documents/overview/tolucombi-epar-summary-public_sl.pdf)

Suomi (FI) (96.93 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/fi/documents/overview/tolucombi-epar-summary-public_fi.pdf)

svenska (SV) (95.99 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

08/04/2013

[View](/sv/documents/overview/tolucombi-epar-summary-public_sv.pdf)

## Product information

Tolucombi : EPAR - Product Information

English (EN) (363.91 KB - PDF)

**First published:** 08/04/2013

**Last updated:** 24/06/2025

[View](/en/documents/product-information/tolucombi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-33)

български (BG) (392.52 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/bg/documents/product-information/tolucombi-epar-product-information_bg.pdf)

español (ES) (475.76 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/es/documents/product-information/tolucombi-epar-product-information_es.pdf)

čeština (CS) (366.89 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/cs/documents/product-information/tolucombi-epar-product-information_cs.pdf)

dansk (DA) (358.49 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/da/documents/product-information/tolucombi-epar-product-information_da.pdf)

Deutsch (DE) (385.64 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/de/documents/product-information/tolucombi-epar-product-information_de.pdf)

eesti keel (ET) (372.82 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/et/documents/product-information/tolucombi-epar-product-information_et.pdf)

ελληνικά (EL) (404.23 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/el/documents/product-information/tolucombi-epar-product-information_el.pdf)

français (FR) (380.29 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/fr/documents/product-information/tolucombi-epar-product-information_fr.pdf)

hrvatski (HR) (357.47 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/hr/documents/product-information/tolucombi-epar-product-information_hr.pdf)

íslenska (IS) (355.71 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/is/documents/product-information/tolucombi-epar-product-information_is.pdf)

italiano (IT) (463.66 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/it/documents/product-information/tolucombi-epar-product-information_it.pdf)

latviešu valoda (LV) (365.35 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/lv/documents/product-information/tolucombi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (368.6 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/lt/documents/product-information/tolucombi-epar-product-information_lt.pdf)

magyar (HU) (380.7 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/hu/documents/product-information/tolucombi-epar-product-information_hu.pdf)

Malti (MT) (455.6 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/mt/documents/product-information/tolucombi-epar-product-information_mt.pdf)

Nederlands (NL) (492.14 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/nl/documents/product-information/tolucombi-epar-product-information_nl.pdf)

norsk (NO) (354.88 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/no/documents/product-information/tolucombi-epar-product-information_no.pdf)

polski (PL) (384.69 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/pl/documents/product-information/tolucombi-epar-product-information_pl.pdf)

português (PT) (372.24 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/pt/documents/product-information/tolucombi-epar-product-information_pt.pdf)

română (RO) (384.03 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/ro/documents/product-information/tolucombi-epar-product-information_ro.pdf)

slovenčina (SK) (379.41 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/sk/documents/product-information/tolucombi-epar-product-information_sk.pdf)

slovenščina (SL) (350.45 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/sl/documents/product-information/tolucombi-epar-product-information_sl.pdf)

Suomi (FI) (355.81 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/fi/documents/product-information/tolucombi-epar-product-information_fi.pdf)

svenska (SV) (435.12 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

24/06/2025

[View](/sv/documents/product-information/tolucombi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000242380 19/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tolucombi : EPAR - All Authorised presentations

English (EN) (34.91 KB - PDF)

**First published:** 08/04/2013

**Last updated:** 28/09/2020

[View](/en/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-744)

български (BG) (73.74 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/bg/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_bg.pdf)

español (ES) (38.63 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/es/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (46.93 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/cs/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (40.01 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/da/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (36.47 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/de/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (38.24 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/et/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (68.53 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/el/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_el.pdf)

français (FR) (44.44 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/fr/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (49.77 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/hr/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (40.16 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/is/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (36.15 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/it/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (68.54 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/lv/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (66.74 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/lt/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (65.04 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/hu/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (61.96 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/mt/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (38.93 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/nl/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (37.99 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/no/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_no.pdf)

polski (PL) (55.61 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/pl/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_pl.pdf)

português (PT) (44.1 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/pt/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_pt.pdf)

română (RO) (58.04 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/ro/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (47.75 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/sk/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (48.68 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/sl/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (40.96 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/fi/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (37.1 KB - PDF)

**First published:**

08/04/2013

**Last updated:**

28/09/2020

[View](/sv/documents/all-authorised-presentations/tolucombi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tolucombi Active substance

- telmisartan
- hydrochlorothiazide

International non-proprietary name (INN) or common name

- telmisartan
- hydrochlorothiazide

Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09DA07

### Pharmacotherapeutic group

telmisartan and diuretics

### Therapeutic indication

Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

## Authorisation details

EMA product number EMEA/H/C/002549

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Krka, d.d., Novo mesto

Šmarješka cesta 6

Opinion adopted 17/01/2013 Marketing authorisation issued 13/03/2013 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tolucombi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.44 KB - PDF)

**First published:** 24/06/2025

[View](/en/documents/procedural-steps-after/tolucombi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tolucombi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (143.5 KB - PDF)

**First published:** 23/07/2014

**Last updated:** 24/06/2025

[View](/en/documents/procedural-steps-after/tolucombi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tolucombi-H-C-2549-A31-0007 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 26/09/2014

**Last updated:** 26/09/2014

[View](/en/documents/variation-report/tolucombi-h-c-2549-a31-0007-epar-assessment-report-article-31_en.pdf)

Tolucombi-H-C-2549-A31-0007 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

English (EN) (48.81 KB - PDF)

**First published:** 26/09/2014

**Last updated:** 26/09/2014

[View](/en/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_en.pdf)

[Other languages (22)](#file-language-dropdown-216)

български (BG) (87.49 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/bg/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/es/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/cs/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/da/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/de/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/et/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/el/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/fr/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/hr/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/it/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/lv/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/lt/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/hu/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/mt/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/nl/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/pl/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/pt/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/ro/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/sk/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/sl/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/fi/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

26/09/2014

**Last updated:**

26/09/2014

[View](/sv/documents/scientific-conclusion/tolucombi-h-c-2549-a31-0007-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendation_sv.pdf)

## Initial marketing authorisation documents

Tolucombi : EPAR - Public assessment report

Adopted

Reference Number: EMA/84367/2013

English (EN) (323.66 KB - PDF)

**First published:** 08/04/2013

**Last updated:** 08/04/2013

[View](/en/documents/assessment-report/tolucombi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tolucombi

Adopted

Reference Number: EMA/CHMP/6036/2013

English (EN) (118.71 KB - PDF)

**First published:** 18/01/2013

**Last updated:** 18/01/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tolucombi_en.pdf)

#### Related information

- [Renin-angiotensin-system (RAS)-acting agents](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

#### More information on Tolucombi

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### More information on Tolucombi

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 24/06/2025

## Share this page

[Back to top](#main-content)